Artivion Inc
Artivion Inc (AORT) Covered Calls
Artivion Inc trades in the Medical Devices industry with an IV Rank of 11.90%, low versus the past year. AORT's highest covered call setup is the $25.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 30.89% out of the money with 63 days to expiration, a 31.15% return until expiration, and a 180.48% theoretical annualized return. Across the setups shown, annualized returns run from 12.41% to 180.48% at strikes between $20.00 and $25.00, with 63 to 154 days to expiration, as of Nov 13, 2026.
Read more
Running AORT covered calls helps you generate income from Artivion Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AORT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AORT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AORT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AORT covered call is worth writing.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system.
| 2027-01-15 | 63 | 25.00 | 30.89 | 0.05 | 0.60 | 595.00 | 31.15 | 180.48 | -0.26 | +0.16 | 36 | 0.55 |
| 2027-01-15 | 63 | 20.00 | 4.71 | 1.00 | 4.90 | 190.00 | 9.95 | 57.63 | -5.24 | +0.55 | 22 | 3.90 |
| 2027-04-16 | 154 | 20.00 | 4.71 | 0.10 | 4.90 | 100.00 | 5.24 | 12.41 | -0.52 | +0.54 | 0 | 4.80 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV Rank11.90% Low
- Market cap (M$)932
- 52 weeks high-60.41%
- 52 weeks low-0.31%
- Analyst recommendationStrong Buy
1.00 - Target price$38.47
108.28% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2027-02-11
- P/E—
- Future P/E136.43
- EPS (ttm)-0.36
- EPS growth next 5 years21.59%
As of Nov 13, 2026